Eric Bryant | Multibagger Research

24.8K posts

Eric Bryant | Multibagger Research banner
Eric Bryant | Multibagger Research

Eric Bryant | Multibagger Research

@MultibaggerRsch

Deep research on companies with 10x+ potential. Concentrated. Contrarian. | $LMND $TSLA $DUOL $HIMS substack: https://t.co/IinXeA1wlk

Присоединился Ocak 2016
1.5K Подписки4.8K Подписчики
Закреплённый твит
Eric Bryant | Multibagger Research
Eric Bryant | Multibagger Research@MultibaggerRsch·
"Isn't $LMND just another insurtech?" This chart can lay that argument to rest. Customers per employee, 2020–2025: $LMND vs. $ROOT vs. 7 major incumbents. $ROOT is the perfect test case. Same era. Same "insurtech" label. Same direct-to-consumer P&C model. Public company with clean data. $ROOT at 457 customers per employee. GEICO at 568. Progressive at 514. Root IS the incumbent band. Why? $ROOT innovation was telematics — better pricing through driving data. That helped them reach profitability. But it didn't change how many humans they need to operate. Root hired 341 people last year to add 73K policies. $LMND hired 47 to add 570K. That's not a difference of degree. It's a difference of kind. $LMND didn't just digitize the front end. AI Maya underwrites. AI Jim handles claims. The marginal customer costs almost nothing to serve. $ROOT used tech to price better. $LMND used AI to run the company. That's why one curve compounds and the other flatlines. This also kills the bear argument that competitors will "just copy $LMND playbook." $ROOT has been trying for 9 years. Backed by $1.2B+ in funding. Public since 2020. Building technology from scratch with no legacy constraints. And they still ended up in the incumbent band. If a well-funded, tech-native insurtech with zero legacy baggage can't replicate this efficiency curve, what makes anyone think State Farm or Allstate will? $LMND AI-first architecture isn't a feature. It's a compound advantage that gets harder to replicate every quarter — because every new customer, claim, and interaction feeds the models that make the next one cheaper to serve. The moat isn’t JUST the AI operating system running the company. It’s 3 million customers (and growing) training the AI.
Eric Bryant | Multibagger Research tweet media
English
17
26
154
64.9K
Eric Bryant | Multibagger Research
Eric Bryant | Multibagger Research@MultibaggerRsch·
$HIMS 🔴 100 million Americans have obesity. 🔴 80 million deal with hair loss. 🔴 30 million with ED. 🔴 60 million with a mental health condition. 🟢 That’s 270 million addressable cases in these markets alone. $HIMS has 2.5 million subscribers. They’ve captured less than 1% of their initial TAM. This is before the Eucalyptus acquisition adds 775K customers across 5 new countries. This company is just getting started.
Eric Bryant | Multibagger Research tweet media
English
15
27
357
23.6K
Eric Bryant | Multibagger Research
Eric Bryant | Multibagger Research@MultibaggerRsch·
$WIX @Base44 is better known by normal people and seemingly less understood by the investment community. It is essentially the most “normie” friendly vibe coding platform. It is probably the easiest platform to use for regular people to create anything without having any technical expertise.
Maor Shlomo@MS_BASE44

We’re launching Base44 Superagents today. It's our take on agents - pushing the limit on how much work can they shoulder as your coworker.  Baes44 pioneered the "batteries included" approach to vibe coding, giving you everything you need (backend, db, integrations, etc.) with zero setup.  So it only makes sense that we do the same thing for agents.  Looking at the rapid progress over the past few weeks - it became clear that models and agents are now good enough to be truly impactful in our day to day work and life.  But, similar to vibe coding, models need access to the right tooling, the right setup - which creates a reality where most people don't want to power through the integration hell.  The setup, security and limitations for non-technical people are a pain.  Superagents give everybody the power of AI agents. No setup - You talk to it like a coworker. You describe what you want and the agent works for you, 24/7. It can connect to Gmail, Calendar, Stripe, Slack, your CRM and 100+ other services out of the box.   We've been testing this with 20% of our builders for the past few days. The sessions we're seeing are wild. People are using it as a co-developer, a marketing assistant, a data analyst, sometimes all three in the same Conversation. One of our builders set up a morning briefing that pulls her sales data, checks her calendar, and sends her a summary on WhatsApp before she's out of bed. Took her 10 minutes to set up. I've been using mine and it even checked me into my flight to Japan; I just landed in Tokyo. Rolling out to everyone today. Go build one. I'd LOVE some feedback once you get to it

English
0
0
5
433
Eric Bryant | Multibagger Research
Eric Bryant | Multibagger Research@MultibaggerRsch·
Even if peptides don’t become massive as many $HIMS bulls believe they will, the opportunities for $HIMS are limitless. Healthcare is ripe for disruption and AI will accelerate this. $HIMS distribution and vertical integration are its hidden moat that will strengthen over time.
Eric Bryant | Multibagger Research tweet media
English
0
0
20
1.2K
Stock Surgeon
Stock Surgeon@TheStockSurgeon·
@MultibaggerRsch My bank seeing XMR and suddenly asking why I need this much privacy
English
1
0
1
107
Eric Bryant | Multibagger Research
Eric Bryant | Multibagger Research@MultibaggerRsch·
$XMR is the new $BTC. The true people’s currency. $BTC has become captured by too many special interests and its lack of privacy has inherent flaws.
Eric Bryant | Multibagger Research tweet media
English
2
0
3
142
Eric Bryant | Multibagger Research
Eric Bryant | Multibagger Research@MultibaggerRsch·
Most investors still think $ATAI is a speculative psychedelics play. Here’s what actually happened in the last 30 days: ✅ FDA aligned on dual-pivotal Phase 3 design for BPL-003 (intranasal mebufotenin for treatment-resistant depression) ✅ Phase 3 on track for Q2 2026 ✅ EMP-01 (oral R-MDMA) hit primary endpoint in Phase 2a for Social Anxiety Disorder ✅ Breakthrough Therapy designation (Oct 2025) ✅ Redomiciled to Delaware — now a U.S. corp ✅ Added to the NASDAQ Biotech Index ✅ Cash runway into 2029 ✅ New CFO with 25+ yrs life sciences experience 7 analysts cover the stock. Consensus: Strong Buy. Avg price target: ~$15. Stock is $4.
Eric Bryant | Multibagger Research tweet media
English
4
0
34
1.9K
Eric Bryant | Multibagger Research
Eric Bryant | Multibagger Research@MultibaggerRsch·
PATH at a glance: ✅ 83% gross margins ✅ 5.2% FCF yield ✅ $1.44B net cash (23% of market cap) ✅ Share count shrinking 3.16%/yr ✅ Founder-CEO back at the helm ✅ First GAAP profit in company history ✅ 2.9x EV/Revenue while peer median is 8x+ 7 things that shouldn’t coexist at this valuation. What am I missing here?
Eric Bryant | Multibagger Research tweet media
English
4
4
42
3.9K
Eric Bryant | Multibagger Research
Eric Bryant | Multibagger Research@MultibaggerRsch·
$NBIS is the only neocloud constantly under-promising and over-delivering.
Nebius@nebiusai

Nebius and @NVIDIA today announced a strategic partnership to develop and deploy next-gen of hyperscale cloud for AI. NVIDIA will invest $2B in Nebius and support our adoption of NVIDIA accelerated compute, enabling us to deploy more than 5 gigawatts by YE2030.

English
1
2
47
2.2K
Eric Bryant | Multibagger Research
Eric Bryant | Multibagger Research@MultibaggerRsch·
Most shorted enterprise software stock heading into earnings tonight: $PATH at 23% of float. Short interest up 62% in one reporting period. The company has beaten earnings 16 consecutive quarters. Last time shorts got this crowded on a consistent beater was $HIMS at 38%. That worked out well for longs.
English
0
0
35
3.3K